- Home
- GENI vs CNTA Comparison
GENI vs CNTA Comparison
Compare GENI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- CNTA
- Stock Information
- Founded
- GENI 2016
- CNTA 2020
- Country
- GENI United Kingdom
- CNTA United Kingdom
- Employees
- GENI N/A
- CNTA N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- GENI Consumer Discretionary
- CNTA Health Care
- Exchange
- GENI Nasdaq
- CNTA Nasdaq
- Market Cap
- GENI 2.4B
- CNTA 2.3B
- IPO Year
- GENI N/A
- CNTA 2021
- Fundamental
- Price
- GENI $12.87
- CNTA $17.01
- Analyst Decision
- GENI Strong Buy
- CNTA Strong Buy
- Analyst Count
- GENI 15
- CNTA 10
- Target Price
- GENI $13.60
- CNTA $30.56
- AVG Volume (30 Days)
- GENI 6.6M
- CNTA 1.2M
- Earning Date
- GENI 08-06-2025
- CNTA 08-12-2025
- Dividend Yield
- GENI N/A
- CNTA N/A
- EPS Growth
- GENI N/A
- CNTA N/A
- EPS
- GENI N/A
- CNTA N/A
- Revenue
- GENI $558,439,000.00
- CNTA $15,000,000.00
- Revenue This Year
- GENI $23.90
- CNTA N/A
- Revenue Next Year
- GENI $16.01
- CNTA N/A
- P/E Ratio
- GENI N/A
- CNTA N/A
- Revenue Growth
- GENI 25.76
- CNTA 118.88
- 52 Week Low
- GENI $6.72
- CNTA $9.60
- 52 Week High
- GENI $13.10
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- GENI 66.49
- CNTA 54.91
- Support Level
- GENI $12.31
- CNTA $17.01
- Resistance Level
- GENI $13.10
- CNTA $18.14
- Average True Range (ATR)
- GENI 0.52
- CNTA 0.81
- MACD
- GENI -0.01
- CNTA -0.10
- Stochastic Oscillator
- GENI 87.63
- CNTA 51.08
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.